

Article title: Final Overall Survival Analysis of the Phase 3 HERITAGE Study Demonstrates Equivalence of Trastuzumab-dkst to Trastuzumab in HER2-Positive Metastatic Breast Cancer


Journal name: *Breast Cancer Research and Treatment*

Authors: Hope S. Rugo,¹ Eduardo J. Pennella,² Unmesh Gopalakrishnan,³ Miguel Hernandez-Bronchud,⁴ Jay Herson,⁵ Hans Friedrich Koch,⁶ Subramanian Loganathan,⁷ Sarika Deodhar,⁷ Ashwani Marwah,⁷ Alexey Manikhas,⁸ Igor Bondarenko,⁹ Guzel Mukhametshina,¹⁰ Gia Nemsadze,¹¹ Joseph D. Parra,¹² Maria Luisa T. Abesamis-Tiambeng,¹³ Kakhaber Baramidze,¹⁴ Charuwan Akewanlop,¹⁵ Ihor Vynnychenko,¹⁶ Virote Sriuranpong,¹⁷ Gopichand Mamillapalli,¹⁸ Sirshendu Roy,¹⁹ Eduardo Patricio Yanez Ruiz,²⁰ Abhijit Barve,² Adolfo Fuentes-Alburo,² Cornelius F. Waller²¹

Corresponding author: Hope S. Rugo, Professor of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, 1825 4th St, 3rd Floor BCC San Francisco, CA 94158, Hope.Rugo@ucsf.edu

ONLINE RESOURCE 1

Supplementary Figure. Study design.



CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; LVEF, left ventricular ejection fraction; q3w, every 3 weeks. ^aPatients with stable disease could continue with combination therapy beyond 8 cycles. ^bObjective overall response rate (defined as complete or partial response). ^cIncluding overall survival, progression-free survival, and time to progression. ^dTaxanes consisted of either docetaxel 75 mg/m² q3w or paclitaxel 80 mg/m² weekly administered 30 minutes after treatment. ^ePatients with complete or partial response proceeded to the monotherapy

phase of the study and patients with stable disease after ≥ 8 cycles proceeded to the monotherapy phase of the study at the investigator's discretion. 1 cycle = 3 weeks.